CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month
Cel-Sci priced the share offering at $1, a 7.4% discount from the stock’s previous close.
Stocktwits
More News
Why DID CVM Shares Rally Over 7% Today?
According to a filing with the U.S. Securities and Exchange Commission, CEO Kersten Geert R. purchased 38,023 shares in the company on Jan. 22 at $5.26 per share.
Stocktwits
Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine
Multikine is a cancer immunotherapy, which has significantly improved survival in head and neck cancer patients during global Phase 3 trials.
Stocktwits
CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled
The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.
Stocktwits
Cel-Sci Stock Slips After Public Offering: Retail's Neutral
The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.